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Background: Salbutamol, the most widely used short-acting b2-agonist, consists of a
racemic mixture of equal amounts of two enantiomers, (R)-salbutamol and (S)-salbutamol.
The bronchodilator effects of salbutamol are attributed entirely to (R)-salbutamol
(levosalbutamol), while (S)-salbutamol has been shown to possess bronchospastic and
pro-inflammatory effects both in vitro and in vivo studies. Levosalbutamol, the (R)-
enantiomer of salbutamol is currently available only in a liquid formulation for use via a
nebulizer.
Recently, levosalbutamol to be administered via a pressurized metered dose inhaler (pMDI)
has been developed.
Aims: To compare the time-dependent bronchodilator responses of single doses of
100mcg levosalbutamol and 200mcg racemic salbutamol administered via a pMDI in
subjects with stable mild-to-moderate bronchial asthma over a period of 6 h.
Methods: Single doses of 100mcg levosalbutamol, 200mcg salbutamol and placebo were
administered with a pMDI in 30 stable asthmatic subjects in a randomized, double-blind,
placebo-controlled, three-way cross over study. Forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC) were measured at baseline, and over 6 h post-study drug
administration.Published by Elsevier Ltd.
f variance; ATS ¼ American Thoracic Society; AUC ¼ Area under curve; CI ¼ Confidence interval;
ry disease; FEV1 ¼ Forced expiratory volume in 1 s; FVC ¼ Forced vital capacity; L ¼ Liters;
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A. Jantikar et al.846Results: Levosalbutamol and salbutamol produced significantly better bronchodilator
responses than placebo. Both the drugs showed equivalent time-dependent bronchodilator
responses as measured by area under curve for percent change in FEV1 and FVC over 6 h.
The time to onset of action, mean maximum bronchodilator response and duration of
bronchodilator response were similar between levosalbutamol and salbutamol.
Conclusion: A single dose of 100mcg levosalbutamol administered by a pMDI produced a
similar bronchodilator response as salbutamol when measured over 6 h in subjects with
stable, mild-tomoderate bronchial asthma.
& 2006 Published by Elsevier Ltd.Introduction
Salbutamol (Albuterol) is the most widely used short-acting
b2-agonist in the symptomatic relief of asthma and chronic
obstructive pulmonary disease (COPD). In all formulations,
salbutamol consists of a racemic mixture of equal amounts
(50:50) of (R)- and (S)-isomers.1 Although these isomers are
chemically identical, they differ in conformation, being
exact non-superimposable (mirror) images of one another, or
stereoisomers.2 (R)-salbutamol has been shown to have a
2-fold greater binding affinity than racemic salbutamol and
a 100-fold greater binding affinity than (S)-salbutamol for
the b2-adrenergic receptor.
3 As a result, the bronchodilator
property of racemic (R,S)-salbutamol is attributed entirely
to (R)-salbutamol. Clinical studies, especially in children
have shown that levosalbutamol produces a similar bronch-
odilator response as racemic salbutamol even when
administered at one-half or one-fourth the dose.4–9
(S)-salbutamol has no clinically meaningful ability to relax
airway smooth muscle. Pre-clinical studies have suggested
that (S)-salbutamol might antagonize the smooth muscle
relaxing actions of (R)-salbutamol by increasing intracellular
Ca2+ levels.10 (S)-salbutamol given alone has also been
reported to enhance airway hyperresponsiveness to spasmo-
gens in vitro, promote eosinophil recruitment and activa-
tion, increase the production of histamine, and increase
airway smooth muscle contractility.11 These divergent
properties of (R)- and (S)-salbutamol suggest that adminis-
tration of only (R)-salbutamol would have a better ther-
apeutic index than racemic salbutamol.
Although levosalbutamol [(R)-salbutamol] has been intro-
duced in the management of asthma and COPD since 1999, it
is available only in a liquid formulation to be administered
by a nebulizer. The pressurized metered dose (pMDI) inhaler
is the most widely used device for drug delivery in patients
with asthma. It is convenient, cheap, easy to use and
effective.12 Salbutamol administered via pMDI is widely used
in the management of symptomatic relief of acute asthma,
and when administered via a spacer, is as effective as that
administered via a nebulizer in patients with acute severe
exacerbations.13 Recently, levosalbutamol has been devel-
oped to be delivered via a pMDI (50mcg per puff). The aim
of this study was to compare the time-dependent bronch-
odilator effects of single doses of 100mcg levosalbutamol
and 200mcg racemic salbutamol, both administered by a
pMDI in subjects with chronic stable mild-to-moderate
asthma.Study design
Male and female stable asthmatic subjects between the age
groups of 18–65 years were recruited into the study. Asthma
was defined according to American Thoracic Society (ATS)
criteria (history suggestive of asthma, improvement in
forced expiratory volume in 1 s (FEV1) of at least 12% and
200mL with 200mcg racemic salbutamol).14 All the study
subjects were non-smokers and none of them received oral
steroids or had an acute asthma exacerbation 4 weeks prior
to the start of the study. Those subjects who were on regular
(at least 4 weeks duration) inhaled corticosteroids were
allowed to continue with their medication at the same dose
throughout the entire duration of the study. All subjects had
a baseline FEV1 of at least 60% predicted [calculated as per
European Community for Coal and Steel (ECCS) X 0.9]15 and
underwent assessment for the proper use of a pMDI.
Pregnant and lactating women were exempted from the
study. Peripheral venous blood was analyzed for routine
hemogram and biochemistry during the screening visit to
rule out other associated disorders. The study was approved
by the institutional ethics committee and a written
informed consent was obtained from all study subjects.
Single doses of 100mcg levosalbutamol, 200mcg racemic
salbutamol and placebo (manufactured by Cipla Ltd. India)
were administered on three separate study days, at least 3
days apart, in a randomized, double-blinded, crossover
manner via a pMDI and a non-static spacer (ZerostatTM
spacer, Cipla Ltd., India). The propellant used in this
study was CFC (Chlorofluorocarbons) comprising of trichlor-
ofluromethane and dichlorofluromethane. Care was taken
to ensure that the subjects had avoided short-acting
b2-agonists for at least 8 h and long-acting b2-agonists and
oral theophyllines for at least 24 h prior to the start of the
study visits. Lung function parameters (FEV1 and forced vital
capacity (FVC)) were measured before (baseline values) and
5, 15, 30, 60, 120, 240 and 360min after the study drug
administration using a volume-based bellows Gold Standard
Vitalographs Spirometer. The lung function tests were
performed by a trained lung function technician using ATS
guidelines.16 The highest FEV1 value at each time point was
considered for analysis. The difference of up to 12% in the
baseline FEV1 between the two study visits was accepted.
Blood was collected for the measurement of serum
potassium levels before and 1 h after the administration of
the study medications. Pulse rate was measured before, 1
and 6 h after the administration of study drug medications.
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Table 1 Demographic details of study subjects.
Variables Mean (SD)
Mean age (years) 44.8 (11.0)
Sex 17 males, 13 females
Mean FEV1 (SD) L 1.70 (0.55)
Mean FVC (SD) L 2.73 (0.86)
Mean FEV1/FVC (SD) 70.54 (5.73)
FEV1 reversibility (SD) as
percentage
17.61 (4.87)
(FEV1: forced expiratory volume after 1 s, FVC: forced vital
capacity, L: litres, SD: standard deviation).
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Figure 1 Mean percentage change in FEV1 values over a period
of 6 h following single dose administration of levosalbutamol,
racemic salbutamol and placebo.
Bronchodilator effect of pMDI levosalbutamol 847The primary efficacy parameter was the mean difference
in area under the curve (AUC) for percent change in FEV1
and FVC from baseline to 6 h. The secondary efficacy
parameters were the mean maximum FEV1 and FVC change
from baseline, time to onset of response, time to maximum
response and duration of response. The time to onset of
bronchodilator response was defined as an increase in FEV1
of 12% and 200mL from the baseline value, while the
duration of action was taken as the previous time point
when the fall in FEV1 was at least 200mL from the baseline
value. The safety parameters assessed were mean changes
in pulse rate and serum potassium levels from baseline
values to 1 h after study medications.
Sample size estimation for this study was done using a PS
(Power and Sample Size) Software Version 2.1.31 (Vander-
bilt, Canada) considering the mean maximum change in FEV1
following salbutamol administration from our previous
study. A sample size of 24 was required to detect differences
between study medications with 80% power to show
equivalence at a significance level of 5%.
Spirometric data (FEV1, FVC) for each study treatment
were analyzed using student’s t-test for paired variables.
The mean response to all treatments was compared by
multi-factorial analyses of variance (ANOVA) to determine
the overall effect of interventions. Duncan’s multiple range
testing with 95% confidence interval (CI) was used where the
differences were significant (Po0.05). The AUC for FEV1 was
calculated for each subject during each study treatment
using the trapezoidal rule. The mean difference in the AUC
for the two treatment groups were analyzed using ANOVA
approach for Schuirmann’s two one-sided test of equiva-
lence. Equivalence was accepted if the mean difference
with 95% CI’s of the study variables were contained within
the set limits. An independent statistician who was blinded
to the codes for the study medications performed the
statistical analysis. The medication codes were broken at
the end of the complete analysis.Results
Forty-two subjects were screened for the study and 30 were
randomized (11 subjects did not meet the criteria for either
airflow reversibility or percent FEV1 predicted, while one
subject withdrew consent). All the subjects completed the
study without any significant adverse effects. The mean age
of the study population was 44.8 (711.0) years. The
summary of the demographic details is shown in Table 1.
There was no significant difference in the baseline FEV1
values on the 2 study days (mean7SD for levosalbutamol was
1.7570.63 and racemic salbutamol was 1.7770.66;
P ¼ 0:28).
Single doses of 100mcg levosalbutamol and 200mcg
racemic salbutamol produced a significantly better time-
dependent bronchodilator response as measured by AUC
percentage change for FEV1 and FVC from baseline to 6 h
when compared to placebo (P values o0.0001 for FEV1 and
o0.0001 for FVC) (Fig. 1). The mean differences in AUC for
percent change in FEV1 and FVC between racemic salbuta-
mol and levosalbutamol from baseline to 6 h were not
significant [(FEV1 AUC06 h: 7486.3 versus 7493.6 for levo-
salbutamol and salbutamol respectively; P40:05) (FVCAUC06 h: 3814.8 versus 3463.2 for levosalbutamol and
salbutamol, respectively; P40:05)] (Fig. 1 showing FEV1%
change), suggesting that 100mcg levosalbutamol and
200mcg racemic salbutamol produced equivalent broncho-
dilator responses over 6 h.
The mean maximum difference for FEV1 from baseline
was 537mL with levosalbutamol and 538mL with racemic
salbutamol, while the mean maximum difference for FVC
was 456 and 417mL, respectively (Fig. 2). These differences
were not statistically significant, suggesting that 100mcg
levosalbutamol and 200mcg racemic salbutamol produced
an equivalent mean maximum increase in FEV1 and FVC.
Levosalbutamol took 58.3 and 52.6min to reach the
maximum FEV1 and FVC response, while racemic salbutamol
took 67.5 and 64.3min, respectively. These differences
were not statistically significant when compared to each
other (P ¼ 0:94). The time to onset for the bronchodilator
response (increase of at least 200mL and 12% in FEV1 from
baseline) for levosalbutamol was 12min, while that for
racemic salbutamol was 18min and the differences between
the two were not significant. The mean duration of
response (difference between onset and termination of
effect) for levosalbutamol was 208min and for racemic
salbutamol was 212min. This difference was not statisti-
cally significant (P ¼ 0:75), suggesting that there was no
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Figure 2 Mean maximum increase in FEV1 from baseline after
administration of placebo, racemic salbutamol and levosalbu-
tamol.
A. Jantikar et al.848difference in the duration of bronchodilator response
between the two study drugs.
Both levosalbutamol and racemic salbutamol produced a
significant decrease in serum potassium level 1 h after study
drug administration compared to their respective baseline
values, (4.61–4.25; Po0.001 and 4.39–4.13; P ¼ 0:004,
respectively). The placebo treatment did not show any
significant decline in serum potassium levels (4.47–4.37;
P ¼ 0:19). Racemic salbutamol and levosalbutamol 60min
post-drug administration both produced a significant in-
crease in pulse rate versus their baseline, (73.9–77.8 beats/
min; Po0.05 and 72.4–77.3 beats/min; Po0.05, respec-
tively). There was no significant difference in the pulse rate
6 h post-drug administration compared to baseline values
(data not shown).Discussion
In this randomized, double-blind, placebo-controlled, cross-
over study, we have demonstrated for the first time that a
single dose of 100mcg of levosalbutamol administered via a
pMDI produced a similar time-dependent bronchodilator
response as that of 200mcg racemic salbutamol in subjects
with mild-to-moderate stable asthma. The time to onset of
bronchodilator response, mean maximum change in FEV1
and FVC, time to reach the mean maximum FEV1 and FVC
responses and the duration of responses were similar
between the two study medications. Both the drugs
increased pulse rate and reduced serum potassium levels
equally, when measured 1 h after administration.
Salbutamol is the most widely used inhaled short-acting
b2-agonist in the symptomatic relief of asthma and COPD. It
consists of a racemic mixture of equal amounts of (R)- and
(S)-enantiomers. These enantiomers have similar physical
and chemical properties, but have different receptor
specificity and therefore have different pharmacological
and physiological effects. The bronchodilator properties of
racemic salbutamol (R,S) have been shown to be attributed
entirely to the (R)-enantiomer. Human epinephrine pro-
duced by the adrenal gland occurs only in the (R)-isomer
form. Clinical studies have demonstrated that the bronch-
odilator and bronchoprotective effects of racemic salbuta-mol in subjects with asthma lie entirely with the (R)-isomer,
with the (S)-isomer being inert. Moreover, in vitro cellular
data have implicated (S)-salbutamol as a possible cause of
airway hyperreactivity, bronchoconstriction or inflamma-
tion,17,18 perhaps induced by stimulating intracellular
calcium accumulation and inhibiting adenyl cyclase.6,19,20
These pre-clinical findings have been confirmed in some
clinical studies that show a greater bronchodilation with
levosalbutamol compared to salbutamol when given either
as a long-term therapy6 (4 weeks) or when given in a single
dose.19 This leads to an increase in the therapeutic index of
levosalbutamol when compared to racemic salbutamol.
These divergent pharmacologic properties form the scien-
tific rationale for the potential advantages of levosalbuta-
mol over racemic salbutamol in the treatment of asthma and
other airway disorders.
Until recently, optically pure isomers of b2-agonists were
not available or were not thought necessary for optimum
clinical safety or efficacy in acute asthma treatment. The
availability of purified (R)-salbutamol (levosalbutamol) and
the United States Food and Drug Administration’s position to
quantify the safety of racemic drugs have generated
renewed interest in the role of inert isomers. In this study,
we compared the bronchodilator effects of single doses of
100mcg levosalbutamol and 200mcg racemic salbutamol
administered via a pMDI in subjects with asthma over a
period of 6 h. These dosages were used to simulate those
used in routine clinical practice. To our knowledge, this is
the first reported study that has investigated the efficacy
and safety of a single dose of levosalbutamol administered
via a pMDI.
Our study demonstrates that 100mcg levosalbutamol
administered in a pMDI formulation is as effective as
200mcg racemic salbutamol, when measured by percentage
changes in FEV1 and FVC AUCs from baseline to 6 h, time to
onset of bronchodilator response, mean maximum change in
FEV1 and FVC and duration of the bronchodilator effect. The
results of this study confirm earlier reports that the
bronchodilator effects of salbutamol are entirely attribu-
table to its (R)-enantiomer.
Although earlier studies 19,20 had suggested that levosal-
butamol might show lesser clinical side effects than the
racemic form, we did not find any difference in pulse rates
and decreases in serum potassium levels between levosal-
butamol and racemic salbutamol. These observations are in
accordance with Lotvall et al.5 who have demonstrated that
the adverse effects of racemic salbutamol on heart rate and
potassium levels are mediated mainly by the (R)-enantio-
mer. Cockcroft et al. have reported that nebulized
levosalbutamol produced similar effects on heart rate as
racemic salbutamol, suggesting that tachycardia caused by
salbutamol is attributed to (R)-salbutamol. Pancu et al.21
have reported that (R)-salbutamol and racemic salbutamol
are equally effective in lowering serum potassium levels.
This study has therefore shown that the bronchodilator
effect and systemic side effects of salbutamol reside with
the (R)-enantiomer. We did not assess tremors. Since we
used single doses of 100mcg levosalbutamol and 200mcg of
racemic salbutamol we did not expect to find significant
numbers of patients experiencing tremors at this small dose.
Also tremor assessment is a subjective observation, which
has its own drawbacks.
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Bronchodilator effect of pMDI levosalbutamol 849In summary, a single dose of levosalbutamol administered
in a pMDI formulation produced an equivalent time-
dependent bronchodilator response over 6 h as racemic
salbutamol at half the dose. Thus, levosalbutamol adminis-
tered in a pMDI formulation may be used routinely for acute
symptomatic relief in subjects with asthma. Further studies
involving larger numbers of patients and for longer duration
are required to determine long-term safety and efficacy of
levosalbutamol administered via a pMDI.References
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